The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for the coming flu seasons.
The decision is likely too late for the next winter season, with most stocks of vaccine having already been ordered in, but could see the quadrivalent vaccine used after that.
The decision marks a serious turnaround, after the last two seasons the CDC had advised against ordering the vaccine, due to a long-term study showing that it proved ineffective against the swine flu outbreak.
